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OBJECTIVE — To assess changes in the quality of care in Norway for patients with type 2
diabetes.
RESEARCH DESIGN AND METHODS — Two cross-sectional surveys were examined
that identiﬁed all patients (n  1,470 in 1995 and n  2,699 in 2005) with type 2 diabetes
attending 33 general practices in 1995 and 2005.
RESULTS — Between1995and2005,thereweresigniﬁcantimprovementsintheproportion
ofpatientsforwhomimportantlaboratoryanalyses,smokinghabits,height,weight,andreferral
to eye examination were recorded. Mean A1C declined from 7.74 to 7.15%, systolic blood
pressure from 150.0 to 140.4 mmHg, and cholesterol from 6.28 to 5.0 mmol/l (P  0.001, age
andsexadjusted).The10-yearriskofcoronaryheartdiseaseforanaveragemalepatientdeclined
from 42 to 29%.
CONCLUSIONS — There have been substantial improvements in type 2 diabetes primary
care in Norway that are potentially related to major improvements in health outcomes.
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I
mproving the quality of diabetes care
has been a major focus of the Norwe-
gian College of General Practice since
the ﬁrst diabetes guidelines for general
practice were published in 1988. Guide-
lines were revised in 1995, 2000, and the
lateautumnof2005(1).Guidelinetargets
for A1C 7.5% and serum cholesterol
5.0 mmol/l remained unchanged from
1995 to 2005, whereas target blood pres-
sure was lowered from 140/90 to
140/85 mmHg in 2000. Our objective
in this study was to assess changes in the
quality of type 2 diabetes care in general
practice from 1995 to 2005.
RESEARCH DESIGN AND
METHODS— Qualityofdiabetescare
wasassessedinacross-sectionalsurveyof
33 practices in 1995 (2). All practices
(n  35) with electronic medical records
in two representative areas of Norway
were selected to take part in the ﬁrst sur-
vey. The same 33 practices agreed to par-
ticipate in the survey of 2005.
All patients with type 2 diabetes in
1995 (n  1,667) and 2005 (n  3,013)
were identiﬁed using electronic search
programs with manual veriﬁcation. Pa-
tients in nursing homes, patients receiv-
ing diabetes care from specialists, and
patients with less than 6 months of fol-
low-up were excluded, leaving 1,470
subjects (49.5% of whom were male) in
1995and2,699(51.2%male)in2005for
analysis. Variables included demographic
data, processes of care, outcomes of care,
and medications. The most recent result
was recorded if more than one value was
available. Variables had identical deﬁni-
tions in both surveys.
Statistical tests were performed using
SPSS version 13. Differences between
means in Table 1 were tested using an
ANOVAanalysisadjustedforageandsex.
Other results were adjusted for clustering
by using practice-speciﬁc proportions or
means as observations in Student’s t test.
The UK Prospective Diabetes Study risk-
engine model (3) was used to calculate
the 10-year risk reduction for coronary
disease.
RESULTS— The majority of patients
were Caucasian (98%). Between 1995
and 2005, mean age decreased (69.1 to
66.3 years; P  0.001), mean diabetes
duration increased (6.6 to 7.0 years; P 
0.047), and mean weight increased (81.1
to 86.1 kg; P  0.001), whereas mean
heightwascomparablebetweenbothsur-
veys. The proportion of patients for
whom important processes of care had
been recorded improved as follows: cho-
lesterol 46 to 88% (difference [] 42%
[95% CI 35–48]; P  0.001), HDL cho-
lesterol 18 to 61% (43% [36–49]; P 
0.001), microalbumin 13 to 33% (20%
[12–27]; P  0.001), smoking habits 13
to 57% (44% [39–50]; P  0.001),
height 13 to 39% (26% [16–36]; P 
0.001),weight38to56%(18%[8–28];
P  0.001), and referral to eye examina-
tion 30 to 74% (44% [37–50]; P 
0.001). A1C and blood pressure were re-
cordedforapproximately90%ofsubjects
in both surveys.
Table 1 shows mean values for risk
factors related to treatment groups and
the proportion of patients achieving na-
tional targets. Treatment was more inten-
sive in 2005 compared with 1995.
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therapy, 23 vs. 12% (11% [95% CI
7–16]; P  0.001) received two or more
oral hypoglycemic agents and 13 vs. 1%
(12% [9–14]; P  0.001) received both
oral hypoglycemic agents and insulin.
Few patients used glitazones (2%) or
acarbose (1%) in 2005. Of patients using
antihyperglycemictherapy,thepercentof
patients with A1C 6.5% increased from
10 to 22% (12% [7–17]; P  0.001).
Among patients treated for hypertension,
64 vs. 29% (35% [30–41]; P  0.001)
received two or more antihypertensive
agents.Morepatientsreceivedaspirin(35
vs. 19%; 16% [12–20]; P  0.001) and
statins (45 vs. 4%; 41% [38–45]; P 
0.001). National targets for treatment of
hyperglycemia, blood pressure, and cho-
lesterol were achieved by signiﬁcantly
more patients in 2005 (Table 1). There
were no clinically important sex differ-
ences in the improvement of risk factor
control or treatment.
Coronary risk reduction was calcu-
lated for an average patient (age 67 years,
nonsmoking, with 7 years’ diabetes dura-
tion)usingmeanvaluesformajorriskfac-
tors in 1995 and 2005. The absolute 10-
year risk reductions were from 42 to 28%
for men and from 39 to 27% for women.
CONCLUSIONS— Risk factor con-
trol has improved considerably. Between
1995 and 2005, reductions in mean val-
ues for A1C, blood pressure, and choles-
terol were 0.6%, 10/4 mmHg, and 1.3
mmol/l, respectively, despite weight gain.
This could be explained by more inten-
sive treatment due to increased impact of
guidelines after the publication of the UK
Prospective Diabetes Study results,
changes in diagnostic criteria, increased
efforts to diagnose diabetes earlier, or a
trend toward healthier living because
blood pressure and cholesterol have de-
creased in the general population of Nor-
way (4). Some of these factors together
with an increase in the prevalence of dia-
betes due to obesity may explain the
markedincreaseinthenumberofpatients
with type 2 diabetes attending the prac-
tices. Very similar reductions in A1C and
blood pressure among patients with type
2 diabetes in general practice have been
reported by the Swedish National Diabe-
tes Register between 1996 and 2005 (5).
AdeclineinA1Cfrom7.8to7.2%between
1999 and 2004 among adult patients with
diabetes in the U.S. has been reported in an
analysis of National Health and Nutrition
Examination Survey data (6). Other studies
(5–10) that have performed the latest sur-
veysince2002reportimprovementsinrisk
factor control, whereas studies reporting in
2002 or earlier (11–14) ﬁnd little or no
improvement.
Improvements in risk factor control,
processes of care, and the more wide-
spread use of metformin suggest that
practitioners are responding to guide-
lines. Apart from educational meetings,
there are no additional incentives for
practitioners to follow national guide-
lines. An independent study has con-
ﬁrmed that the guidelines are used by
52% of general practitioners (15).
Our ﬁndings are probably represen-
Table 1—Treatment groups, risk factors, and patients achieving national targets and differences between 1995 and 2005
Treatment groups
1995 (n  1,470) 2005 (n  2,699)
Differences between
1995 and 2005 P*
Total
patients
Patients
measured Performance
Total
patients
Patients
measured Performance
A1C (%)
Diet alone 30.7 (452) 84.7 (383) 6.75  0.98 28.4 (766) 86.3 (661) 6.46  0.85 0.29 (0.18–0.41) 0.001
Metformin alone 2.2 (33) 87.5 (28) 7.78  1.42 17.3 (467) 94.9 (443) 6.93  0.99 0.85 (0.46–1.24) 0.001
Sulfonylurea alone 33.5 (491) 88.8 (436) 7.74  1.43 12.9 (348) 93.7 (326) 7.16  1.14 0.58 (0.39–0.77) 0.001
Metformin and
sulfonylurea 5.4 (80) 95.0 (76) 8.52  1.86 13.9 (374) 96.5 (361) 7.38  1.06 1.31 (0.82–1.44) 0.001
Insulin alone 25.4 (374) 90.1 (337) 8.52  1.65 15.6 (422) 93.8 (396) 7.79  1.26 0.73 (0.51–0.94) 0.001
Insulin and oral agents 1.1 (17) 100 (17) 8.66  1.61 9.4 (255) 95.3 (243) 7.78  1.30 0.88 (0.20–1.56) 0.011
Overall 88.5 (1,301) 7.74  1.59 92.5 (2,496) 7.15  1.20 0.59 (0.50–0.68) 0.001
SBP (mmHg)
Not on BP-lowering
therapy 52.2 (767) 82.1 (630) 146.2  20.9 34.9 (942) 82.5 (777) 134.9  17.4 11.2 (9.2–13.3) 0.001
BP-lowering therapy 47.8 (703) 91.3 (642) 153.8  22.3 65.1 (1,757) 94.1 (1,653) 143.0  19.5 10.8 (8.9–12.6) 0.001
Overall 86.5 (1,272) 150.0  22.0 90.0 (2,430) 140.4  19.2 9.6 (8.2–10.9) 0.001
Cholesterol (mmol/l)
Not on statin therapy 95.2 (1,399) 46.6 (652) 6.31  1.37 54.3 (1,465) 80.8 (1,184) 5.43  1.08 0.89 (0.77–1.00) 0.001
Statin therapy 4.8 (71) 95.8 (68) 5.99  1.54 45.7 (1,234) 96.1 (1,186) 4.63  1.0 1.36 (1.11–1.62) 0.001
Overall 50 (720) 6.28  1.39 87.8 (2,370) 5.0  1.1 1.26 (1.16–1.35) 0.001
Achievement of national
targets (%)
A1C 7.5% 51.3 69.2 17.9 (12.5–23.3) 0.001
SBP 140 mmHg 46.7 65.7 19.0 (14.5–23.5) 0.001
DBP 85 mmHg 64.5 78.1 13.6 (8.6–18.7) 0.001
Cholesterol 5 mmol/l 16.8 52.9 36.2 (30.7–41.6) 0.001
All four targets 4.2 22.7 18.5 (15.2–21.7) 0.001
Data are % (n), means  SD, or differences (95% CI) unless otherwise indicated. *P values for differences in means of outcome measures are derived from an age-
and sex-adjusted ANOVA analysis. P values for differences in percentage achieving national targets are adjusted for clustering by using practice-speciﬁc means as
proportions in a paired t test. BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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values were reported from a Norwegian
primary care survey in 2004 of 975 pa-
tientsbetween18and75yearsofagewith
type 2 diabetes (8). Furthermore, nearly
identical mean values for A1C, choles-
terol, and blood pressure were found in
twootherregionsofNorwayin2005(n
2,764)atprimarycarecentersthatdidnot
participate in the 1995 survey.
We conclude that there have been
substantial improvements in type 2 dia-
betes primary care in Norway that are po-
tentially related to major improvements
in health outcomes.
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